BACTERIOPHAGE COMPOSITIONS FOR TREATING STAPHYLOCOCCUS INFECTION
The present disclosure relates to bacteriophages and compositions capable of infecting and killing Staphylococcus , and use of the same for treating Staphylococcus , e.g. Staphylococcus aureus , bacterial infections.
1 . (canceled)
2 . An isolated, purified bacteriophage comprising a polynucleotide sequence with at least 90% identity to SEQ ID NO: 1.
3 . (canceled)
4 . An isolated, purified bacteriophage comprising a polynucleotide sequence with at least 90% identity to SEQ ID NO: 2.
5 . The bacteriophage of claim 2 , wherein the bacteriophage is resistant to blood complement inactivation.
6 . A bacteriophage composition comprising one or more bacteriophage selected from a bacteriophage comprising a polynucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 2, a polynucleotide sequence with at least 90% identity to SEQ ID NO: 1, and a polynucleotide sequence with at least 90% identity to SEQ ID NO: 2.
7 . (canceled)
8 . The bacteriophage composition of claim 6 , wherein the bacteriophage infect and kill Staphylococcus aureus.
9 . The bacteriophage composition of claim 6 , further comprising a storage media for storage at a temperature at or below 8° C.
10 . The bacteriophage composition of claim 6 , wherein the bacteriophage is resistant to blood complement inactivation.
11 . The bacteriophage composition of claim 6 , wherein the one or more bacteriophage belong to the genus Silviavirus.
12 . The composition of claim 6 , wherein the composition comprises a bacteriophage comprising a polynucleotide sequence with at least 90% identity to SEQ ID NO: 1.
13 . The composition of claim 6 , wherein the composition comprises a bacteriophage comprising the polynucleotide sequence of SEQ ID NO: 1.
14 . The composition of claim 6 , wherein the composition comprises a bacteriophage comprising a polynucleotide sequence with at least 90% identity to SEQ ID NO: 2.
15 . The composition of claim 6 , wherein the composition comprises a bacteriophage comprising the polynucleotide sequence of SEQ ID NO: 2.
16 . The composition of claim 6 , wherein the composition comprises a bacteriophage comprising a polynucleotide sequence with at least 90% identity to SEQ ID NO: 1 and a polynucleotide sequence with at least 90% identity to SEQ ID NO: 2.
17 . The composition of claim 6 , wherein the composition comprises a bacteriophage comprising the polynucleotide sequence of SEQ ID NO: 1 and a bacteriophage having a genome comprising the polynucleotide sequence of SEQ ID NO: 2.
18 . The bacteriophage composition of claim 6 , wherein the composition is substantially free of a bacterial component.
19 . The composition of claim 18 , wherein the bacterial component comprises bacterial host protein.
20 . The composition of claim 6 , wherein the composition further comprises a pharmaceutically acceptable carrier, diluent, excipient or combinations thereof.
21 . The composition of claim 6 , wherein the composition is a liquid, semi-liquid, solid, frozen, or lyophilized formulation.
22 . The composition of claim 6 , wherein the bacteriophages of the composition target one or more of vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-resistant Staphylococcus aureus (VRSA), methicillin-resistant (MRSA) Staphylococcus aureus.
23 . The composition of claim 22 , wherein the bacteriophages infect and kill one or more of vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-resistant Staphylococcus aureus (VRSA), methicillin-resistant Staphylococcus aureus (MRSA).
24 . The composition of claim 6 , wherein the composition comprises between 1×10 8 and 1×10 11 PFU of each bacteriophage.
25 . The composition of claim 6 , wherein the composition is to be administered at a dosage of at least 1×10 9 PFU of total bacteriophages per milliliter.
26 . The composition of claim 6 , wherein the composition is stored at 2-8° C.
27 . The composition of claim 6 , wherein at least one bacteriophage is obligately lytic.
28 . The bacteriophage of claim 1 , wherein the sequence of at least one bacteriophage is genetically modified.
29 . A method of treating a bacterial infection comprising administering the bacteriophage of claim 1 to a subject in need of treatment.
30 . (canceled)
31 . (canceled)
32 . (canceled)
33 . A bacterial host manufacturing strain comprising a bacteriophage wherein said bacteriophage comprises a polynucleotide sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, a polynucleotide sequence with at least 90% identity to SEQ ID NO: 1, and a polynucleotide sequence with at least 90% identity to SEQ ID NO: 2.
34 . A method of treating a subject with a bacterial infection comprising selecting a bacteriophage based upon resistance to blood complement inactivation and administering said bacteriophage to the subject.
35 . (canceled)
36 . (canceled)
37 . The composition of claim 6 , wherein the composition is formulated for administration to a subject with a bacterial infection.
38 . (canceled)
39 . (canceled)
40 . The composition of claim 6 , wherein the composition is formulated for administration to a subject to target Staphylococcus aureus bacteria.
41 . (canceled)
42 . (canceled)
43 . (canceled)
44 . (canceled)
45 . (canceled)
46 . (canceled)
47 . (canceled)
48 . (canceled)
49 . (canceled)
50 . (canceled)
51 . (canceled)
52 . (canceled)
53 . (canceled)
54 . (canceled)
55 . (canceled)
56 . (canceled)
57 . (canceled)
58 . (canceled)
59 . (canceled)
60 . (canceled)
61 . The composition of claim 6 , wherein the composition is administered intravenously, via intra-articular injection, via inhalation, or via nebulization.
62 . (canceled)
63 . (canceled)
64 . (canceled)
65 . (canceled)
66 . (canceled)
67 . (canceled)
68 . (canceled)
69 . (canceled)